ulloblastoma, colon carcinoma and breast cancer cells.
Introduction and methotrexate. 17 These data suggested that an intact CD95/CD95-L system and CD95 pathway are crucially The molecular pathways that determine sensitivity or resistinvolved in determining sensitivity or resistance towards ance of tumor cells towards anticancer therapy are not well chemotherapy. We therefore analyzed the requirements for understood. Irrespective of intracellular targets, most drug sensitivity in more detail. anticancer drugs have been shown to induce apoptosis in chemosensitive leukemias and solid tumors. 1, 2 The CD95/CD95-L system has been characterized as one of the key signal pathways involved in regulation of apoptosis in several cell types. [3] [4] [5] [6] The CD95 cell surface receptor (CD95) is a Materials and methods 45 kDa type I transmembrane protein, expressed on a variety of cells including activated lymphoid cells. CD95 is a member of the tumor necrosis factor/nerve growth factor (TNF/NGF) Cell lines and culture conditions receptor superfamily of cell surface molecules which mediates apoptosis upon oligomerization. [7] [8] [9] [10] CD95 crosslinking by agonistic antibodies or the natural ligand activates a signal CEM cells were grown in RPMI 1640 (Gibco BRL, Eggenstein, cascade via FADD/MORT-1 and FLICE/MACH that leads Germany) containing 10% fetal calf serum (Conco, Wiesdirectly to activation of ICE/Ced-3 proteases (caspases) which baden, Germany), 10 mM HEPES, pH 7.3 (Biochrom, Berlin, function as downstream effectors of cell death.
11 CD95 ligand Germany), 100 U/ml penicillin (Gibco), 100 g/ml strepto-(CD95-L) is a type II transmembrane molecule of 40 kDa mycin (Gibco) and 2 mm l-glutamine (Biochrom). CEM CD95R , which is also produced as a soluble molecule after proteolytic a variant of CEM resistant towards anti-APO-1 was generated cleavage. [12] [13] [14] In activated T cells an autocrine-suicide-and by continuous culture in anti-APO-1 (anti-CD95) 3 (IgG 3, paracrine-fratricide-mechanism is crucial for maintenance of 1 g/ml) for more than 12 months. CEM DOXOR , a variant of homeostasis, self tolerance and elimination of peripheral T CEM resistant towards doxorubicin was generated by continucells following an immune response. 15 CD95-L which is proous culture in doxorubicin (0.1 g/ml) for more than 8 duced after activation of T cells through T cell receptor trigmonths. For experiments, CEM CD95R cells were washed and cultured for 24 h in the absence of anti-APO-1; CEM Analysis of patient-derived tumor cells transcription and amplified by polymerase chain reaction (PCR) in a thermocycler (Stratagene, Heidelberg, Germany) Cell populations used for ex vivo studies were isolated by using the Gene Amplification kit (Perkin Elmer, Branchburg, Ficoll separation from the peripheral blood of a patient with NJ, USA) following the manufacturer's instructions. Primers hypercellular T cell leukemia (T-ALL) (6 × 10 5 cells/l) and used for amplification of CD95-L fragment were according to from pleural effusion of a patient with T cell non-Hodgkin the sequence of human CD95-L. 21 lymphoma (NHL), respectively, and immediately used for Expression of ␤-actin (MWG-BIOTECH, Ebersberg, further analysis. Both cell populations contained more than Germany) was used as an internal standard for RNA integrity 95% blasts as assessed by immunophenotyping, FACS analysis and equal gel loading. PCR-reaction products were run at was performed by gating on whole population containing 60 V for 2 h on a 1.5% agarose gel stained with ethidium bromore than 95% leukemic cells.
mide and visualized by UV illumination.
Drugs
Western blot analysis Doxorubicin (Farmitalia, Milano, Italy), cytarabine (Mack, Proteins were extracted from cells lysed for 30 min at 4°C in Illertissen, Germany) and methotrexate (Lederle, Wolfrats-PBS with 0.5% Triton X (Serva, Heidelberg, Germany) and hausen, Germany) were provided as pure substances. Doxoru-1 mm PMSF (Sigma) followed by high-speed centrifugation. bicin and cytarabine were freshly dissolved in sterile distilled Membrane proteins were eluated by elution buffer containing water and methotrexate was freshly dissolved in 0.01 n NaOH 0.1 m glycin/HCl, pH 3.0 in PBS and 1.5 m Tris, pH 8.8. Proprior to each experiment to ensure constant quality of the tein concentration was assayed using bicinchoninic acid preparations.
(Pierce, Rockford, IL, USA). One hundred micrograms of protein per lane were separated by 12% SDS-PAGE and electroblotted to nitrocellulose (Amersham, Braunschweig,
Induction of apoptosis
Germany). Equal protein loading was controlled by Ponceau red staining of membranes. After blocking for 1 h in PBS supFor quantitative determination of apoptosis, cells were lysed plemented with 2% BSA (Sigma) and 0.1% Tween 20 (Sigma), in Nicoletti-buffer (0.1% sodium citrate plus 0.1% Triton Ximmunodetection of PARP and CD95-L was done using rabbit 100 containing propidium iodide 50 g/ml) as described. body for 45 min at 4°C. After washing, a second incubation described. 20 The percentage of specific cell death was calculated as step with streptavidin-phycoerythrin (SAPE) (Becton Dickin- Hilden, Germany). RNA was converted to cDNA by reverse body (Transduction Laboratories, Lexington, KY, USA) and
Cross-resistance for CD95-and drug-induced apoptosis in leukemia and tumor cells horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Enhanced chemiluminescence system (ECL) Resistance of tumor cells towards anticancer treatment may result from failure to activate apoptosis pathways in response (Amersham) was used for detection.
to drug treatment. 23 We therefore asked whether resistance to physiological death signaling such as CD95-induced apoptosis is associated with cross-resistance to therapeutic Quantitative analysis of doxorubicin accumulation concentrations of cytotoxic drugs. We generated CEM CD95R , Jurkat CD95R and SHEP CD95R resistant cells, a variation of leukeParental CEM and the derivative cell lines, CEM CD95R (CD95-mia cells (CEM and Jurkat) and neuroblastoma cells (SHEP), resistant) and CEM DOXOR (doxorubicin-resistant) cell line were resistant to anti-APO-1, from the parental cells by continuous incubated with doxorubicin (0.1 g/ml) for 24 h. After 24 h culture in the presence of agonistic anti-APO-1 (1 g/ml) anticells were washed twice with medium, resuspended in fresh body for more than 12 months. CD95-resistant cells showed medium again without doxorubicin and incubated for 24 h at an increased resistance to cytotoxic drugs such as doxorubicin 37°C and 5% CO 2 . By means of autofluorescence of in comparison to parental cells ( Figure 2 ). To investigate doxorubicin, doxorubicin uptake at 24 h and doxorubicin whether drug-resistant cells are also cross-resistant to antiefflux 24 h later were measured by FACScan analysis.
APO-1 we generated CEM DOXOR and SHEP DOXOR , a variation of CEM and SHEP cells, respectively, resistant to therapeutic concentrations of doxorubicin for over 8 months. Doxorubicin-resistant cells showed strong cross-resistance to antiResults APO-1 in comparison to parental cell lines ( Figure 3 ). This result suggests that apoptosis triggered by drugs or anti-APO-CD95-and drug-induced apoptosis in ex vivo derived 1 required, at least in part, identical molecular pathways. To
T-ALL/NHL cells see whether resistant cells did not only exhibit delayed kinetics of apoptosis induction but remained capable of proliferative expansion, cell viability and cell counts were analyzed So far, most of the experimental evidence supporting the role of the CD95 system in drug-induced apoptosis has been daily following treatment of CD95-resistant cells with doxorubicin and doxorubicin-resistant cells with anti-APO-1. While obtained using cell lines.
1,2 We therefore investigated CD95 sensitivity, drug sensitivity and drug-mediated induction of in parental cell lines no viable cells were detected 3 days after doxorubicin treatment, CD95-resistant and doxorubicin-resist-CD95-L expression in ex vivo-derived tumor cells. Treatment of malignant cells from two patients with acute T cell leukeant cells were able to survive and proliferate even in the continuous presence of doxorubicin or anti-APO-1 ( Figure 4 ). mia (T-ALL) and T cell non-Hodgkin lymphoma (NHL) with anti-APO-1 (anti-CD95) ex vivo induced apoptosis over a So far resistance mechanisms have mainly been attributed to overexpression of p-glycoprotein (P-gp, MDR-1) or imbalbroad range of concentrations of the antibody (Figure 1a) . Apoptosis was also induced by incubation with doxorubicin ance of anti-apoptotic and pro-apoptotic Bcl-2 family memat therapeutic concentrations (0.01-1 g/ml) as measured by foreward/sidescatter (FSC/SSC) analysis (Figure 1b) . Since we previously found that drug-induced apoptosis in cell lines depends on gene expression or protein synthesis, 17 we analyzed doxorubicin-induced apoptosis in the presence of the protein synthesis inhibitor cycloheximide. 17 Cells were preincubated with 0.1 g/ml cycloheximide for 1 h at 37°C prior to addition of drugs. Cycloheximide strongly reduced doxorubicin-induced apoptosis (Figure 1c) . In parallel, we asked whether drug treatment of tumor cells from these patients stimulated CD95-L expression as previously shown in leukemia cell lines. 17 Incubation with different drugs (methotrexate (MTX), doxorubicin (DOXO), cytarabine (CYT)) at therapeutic concentrations induced strong up-regulation of CD95-L mRNA after 2 h as shown by reverse transcriptase polymerase bers. 16 MDR-1 acts as a membrane pump leading to increased drug efflux from target cells. 24, 25 To see whether altered drug accumulation may account for drug resistance, we measured CD95-L mRNA and protein were found in resistant cells. This suggests that defective production of CD95-L contributes to drug-resistant cells (Figures 6 and 7) . Furthermore, while parental SHEP cells increase the level of CD95 expression after drug resistance of tumor cells. Deficient activation of the CD95 system by drugs or antitreatment with anticancer drugs such as cisplatin, no increase in CD95 expression after drug treatment was found in resistant APO-1 in resistant cells was also reflected by the ability to cleave the nuclear enzyme poly(ADP-ribose) polymerase cells (data not shown). This suggested that critical levels of CD95 expression and the ability to up-regulate CD95 are (PARP), an enzyme involved in DNA repair and one of the known substrates for caspases. 26 PARP was processed to its required for apoptosis sensitivity to drugs and anti-APO-1.
We recently demonstrated that CD95-L is produced in characteristic 85 kDa fragment by cytotoxic drugs or anti-APO-1 in chemosensitive cells but not in doxorubicin-resistchemosensitive tumor cells in response to drug treatment and mediates drug-induced apoptosis. 17 We therefore asked ant cells after anti-APO-1 treatment or CD95-resistant cells after drug treatment (Figure 9 ). whether anticancer drugs would also induce CD95-L Taken together, these findings suggested that induction of CD95-L, critical levels of CD95 expression and full activation of the downstream effector pathways that involve caspases are induced as previously shown for leukemia cell lines. 17 Furthermore, inhibition of the conserved downstream effector required for chemosensitivity towards chemotherapy in tumor cells such as certain leukemias and neuroblastoma cells. pathway of apoptosis mediated by caspases abrogates drugtriggered apoptosis in patient-derived tumor cells as well as in cell lines. These results show that in tumor cells from patients, as in leukemia cell lines, induction of CD95-L, bindDiscussion ing to its receptor and complete activation of the downstream effector pathways (caspases) are crucially involved in drugCytotoxic drugs induce apoptosis in chemosensitive leukemias and solid tumors. 1, 2 We previously identified the induced apoptosis in chemosensitive tumor cells. Primary or secondary resistance to chemotherapy is a cen-CD95/CD95-L system as a key mechanism for drug-induced apoptosis in different cell lines.
17 CD95-L is up-regulated tral problem in cancer treatment. 27 Failure to activate apoptosis programs in response to drug treatment may be a upon drug treatment and plays a crucial role in triggering apoptosis. 17 Here, we report that therapeutic concentrations major mechanism of resistance to chemotherapy. 23 We report that the CD95 pathway plays a key role in determining sensiof doxorubicin, methotrexate, and cytarabine induce apoptosis via the CD95/CD95-L system also ex vivo in T-ALL tivity or resistance towards chemotherapy. Resistance to physiological death signaling such as CD95-induced and NHL cells. Cycloheximide almost strongly reduced druginduced apoptosis in patient-derived cells demonstrating that apoptosis is associated with cross-resistance to therapeutic concentrations of chemotherapeutic agents. In addition, drug drug-mediated apoptosis depends on gene expression or protein synthesis. Upon drug treatment CD95-L was strongly resistance is also associated with cross-resistance to anti-APO- drug-induced death and CD95-induced apoptosis in some sysstained with biotinylated anti-APO-1 followed by streptavidin-phycotems. 16 However, no differences in the expression levels of gp, MDR-1 24, 25, 27 or deficient function of p53 23 are known to confer resistance to tumor cells. Multidrug resistance is defined by the simultaneous acquisition of cellular resistance 1. This demonstrates that triggering of cell death either by anti-APO-1 or by cytotoxic drugs requires, at least in part, identical to various cytotoxic drugs. Overexpression of P-gp, MDR-1 in cell lines leads to a decrease in intracellular accumulation of molecular effector pathways. Cell lines, resistant to therapeutic concentrations of cytotoxic drugs or anti-APO-1 show drugs concomitant with an increase in drug efflux. 24, 25, 27 However, resistant cells did not exhibit different drug uptake marked down-regulation of CD95 expression in comparison to sensitive parental cells, suggesting that critical levels of or drug efflux in comparison to sensitive parental cells ( Figure  5 ). Furthermore, no overexpression of P-gp, MDR-1 in resist-CD95 expression are required for apoptotic signaling and chemosensitivity. In addition, we found that up-regulation of ant cells was found (data not shown). Thus, the failure to upregulate CD95-L and to undergo apoptosis in response to drug CD95-L expression upon drug treatment, that mediated apoptosis in chemosensitive cells, was inhibited in drug-resisttreatment in resistant cells is not due to decreased drug uptake or increased drug efflux, suggesting that non-MDR mechant and CD95-resistant tumor cells. Apoptosis induced by a variety of stimuli including the CD95 pathway requires actianisms are involved in this type of resistance. The p53 protein has been implicated in the cell death response to ␥-irradiation vation of caspases as effector molecules that cleave substrates such as PARP, an enzyme involved in DNA repair. 26 Preand cytotoxic drugs. 30 By its transcriptional activity, p53, which accumulates during cytotoxic damage of cells may viously, proteolytic cleavage of PARP has been demonstrated following treatment of chemosensitive cell lines with induce expression of genes involved in apoptosis pathways. 31 Thus, p53 has been shown to express CD95. 32 Deficient funcanticancer drugs. 28 In resistant cells no activation of caspases and proteolytic cleavage of PARP was found after treatment tion of p53, eg by mutations, is thought to mediate drug-resistance in several instances. 23, 30 However, in resistant CEM and with drugs or anti-APO-1. This demonstrated that downstream effector pathways required for drug-mediated death in chemo-SHEP cells p53 protein still accumulates following drug treatment suggesting that down-regulation of CD95 and failure to sensitive cells are not activated in resistant cells.
Failure to activate the CD95 pathway and the caspase effecexpress CD95-L following drug treatment are not caused by deficient p53 (data not shown). So far, the molecular pathways tors could be due to imbalanced expression of members of the Bcl-2-family of apoptosis modulating proteins. 29 Thus, that induce expression of CD95-L have not been charac-
